"Designing Growth Strategies is in our DNA"
Diphtheria is a contagious disease caused by bacterium Corynebacterium diphtheria that infects the mucous membranes of nose, throat, upper airway tracts and produces toxins that affect the other organs. The diphtheria toxin causes the membrane of dead tissue to build up over the throat that makes swallowing and breathing of the patient difficult. Diphtheria is caused only among humans and spreads easily through physical contact with the affected person. The symptoms of diphtheria are fever, swollen glands in the neck, a sore throat, bluish skin, and weakness. Complications of diphtheria include blockage of the airway, damage to heart muscles, lung infection, and others.
Currently, the treatment for diphtheria includes intervention of antitoxin or antibiotics. Erythromycin is the first-line therapy. Intramuscular penicillin and diphtheria antitoxin are further recommended at a later stage of the disease. Vaccination against diphtheria has been the most effective way of treatment and prevention of the disease. Vaccines available are DTaP, Tdap, DT, and Td. DTap is a vaccine for pediatrics, whereas Tdap is an adult vaccine.
Awareness about prevention of diphtheria in patients and demand for more vaccinations against the disease is boosting the pharmaceutical industries to accelerate their R&D in the development of effective vaccines for the treatment of diphtheria. For instance; GSK2036874A vaccine is being studied by GlaxoSmithKline Plc. and is currently in phase-2 clinical-stage to evaluate the immunogenicity, safety, and efficacy of the vaccine in treatment of diphtheria.
To know how our report can help streamline your business, Speak to Analyst
At present, around 54% of the pipeline candidates for diphtheria are in phase 3 clinical stage. Pharmaceutical industries are the major sponsor for research on diphtheria.
The report on ‘Diphtheria– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Diphtheria. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for diabetic neuropathic pain.
The report on ‘Diphtheria– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.